research use only

Etretinate Retinoid Receptor agonist

Name: Etretinate
Brand: Selleck Chemicals
SKU: S4699
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.S4699

Etretinate (Tegison, Ethyl etrinoate, Retinoid, Etretinato,Ro 10-9359) is an oral aromatic retinoid acid which is effective in psoriasis and other dermatological syndromes. It activates retinoid receptors, causing an induction of cell differentiation, inhibition of cell proliferation, and inhibition of tissue infiltration by inflammatory cells.

Chemical Structure

Molecular Weight: 354.48

Jump to

Quality Control

Batch: S469901 DMSO]70 mg/mL]false]Ethanol]70 mg/mL]false]Water]Insoluble]false Purity: 99.06%

Cited in Nature Medicine for its top-tier quality
COA
HPLC
SDS
Datasheet

99.06

Related Targets	Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism
Other Retinoid Receptor Inhibitors	TTNPB (Arotinoid acid) Tamibarotene AM580 SR 11237 UVI 3003 Fenretinide BMS493 AR7 Palovarotene CD1530

Solubility

In vitro
Batch:

DMSO : 70 mg/mL (197.47 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 70 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	354.48	Formula	C₂₃H₃₀O₃	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	54350-48-0	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	Tegison, Ethyl etrinoate, Retinoid, Etretinato,Ro 10-9359			Smiles	CCOC(=O)C=C(C)C=CC=C(C)C=CC1=C(C(=C(C=C1C)OC)C)C

Mechanism of Action

Targets/IC₅₀/Ki	RAR
In vivo	There is a significant decrease in mean dermal thickness (P < 0.05) and changes in collagen bundles in the etretinate-treated mice group for a 28-day period compared to control groups. TUNEL assay shows that the density of TUNEL-positive cells in the dermis of etretinate-treated mice for a 14-day period is significantly increased (P < 0.05). The ratio of procollagen α 1 (I) chain to β actin mRNA from etretinate-treated mice for a 1-day period decreased significantly compared to that of the control mice, but the ratio from etretinatetreated mice for a 14-day period increased significantly (P < 0.05). Etretinate reduces dermal thickness, and suppresses the appearance of skin lesions by inducting apoptosis and perhaps regulation of cytokine expression in MRL/lpr mice.
References	[1] https://pubmed.ncbi.nlm.nih.gov/19077103/ [2] http://www.sciencedirect.com/science/article/pii/S1323893015310546 [3] https://pubmed.ncbi.nlm.nih.gov/16130505/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04582383	Recruiting	Acne	University of Pennsylvania	March 30 2022	Phase 4
NCT04018144	Unknown status	Periodontitis	Tokat Gaziosmanpasa University	August 1 2019	--
NCT04020146	Completed	Periodontitis\|Periimplantitis	Tokat Gaziosmanpasa University	January 10 2018	--
NCT02847533	Unknown status	Depression	Centre Hospitalier Universitaire de Besancon	September 2016	Not Applicable
NCT02620813	Completed	Acne Vulgaris	University of California Davis	October 2015	Early Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):